The potentially curative promise of gene therapies often carries a steep price tag. But for a pair of personalized medicine prospects in sickle cell disease (SCD), the cost could be worth it, at least ...
The world’s first CRISPR-based gene-editing therapy appears to be nearing the market. And an influential drug cost watchdog has an early idea of how the treatment should be priced to be considered ...
April 12 (Reuters) - Vertex Pharmaceuticals Inc (VRTX.O), opens new tab and CRISPR Therapeutics AG's (CRSP.BN), opens new tab one-dose gene editing therapy for sickle cell disease would be cost ...
July 13 (Reuters) - An influential U.S. drug pricing watchdog raised the price estimate of two experimental gene therapies from Vertex Pharmaceuticals (VRTX.O), opens new tab/CRISPR Therapeutics and ...
For some diseases, gene therapies offer the potential for lifelong disease amelioration and even cure. And these immensely important novel biotechnologies may be on the cusp of a boom. That is in part ...
Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of ...
Gene editing and gene therapy stocks have been among the hardest hit during the biotech downturn in 2022. What's behind this sudden trend reversal? The most likely explanation is simply short-sellers ...
(Reuters) -Vertex Pharmaceuticals Inc and CRISPR Therapeutics AG's one-dose gene editing therapy for sickle cell disease would be cost effective if priced at up to $1.9 million, an influential U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback